Literature DB >> 6319069

Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function.

D Kampf, K Borner, M Möller, M Kessel.   

Abstract

Cefotaxime (CTX) kinetics, alone and in combination with azlocillin (AZ), were determined in 18 subjects with either normal or impaired renal function. After the single dose and with increasing renal insufficiency, total CTX clearance fell from 266 to 71 ml/min/1.73 m2. At the same time the terminal t1/2 rose from 1.1 to 2.8 hr. Regardless of the degree of renal function, CTX clearance in combination with AZ in all patients was only 50% to 60% of that with CTX alone. This reduction in total body clearance was due to a parallel decrease in renal and nonrenal clearance. In advanced renal failure, particularly after AZ, the terminal t1/2 of the CTX metabolites increased up to 1000% to 1500% of normal. On the basis of these findings, CTX dosage adjustment is recommended only in patients with a glomerular filtration rate (GFR) below 20 ml/min. After AZ, however, dosage reduction of CTX seems to be advisable at an earlier stage of renal impairment (GFR 40 ml/min).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6319069     DOI: 10.1038/clpt.1984.29

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin.

Authors:  S L Barriere; D H Catlin; P L Orlando; A Noe; R W Frost
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 3.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

4.  Pharmacokinetics of cefotaxime in patients after liver transplantation.

Authors:  E Kuse; P Vogt; B Rosenkranz
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

5.  Mixed Micelles Loaded with Bile Salt: An Approach to Enhance Intestinal Transport of the BCS Class III Drug Cefotaxime in Rats.

Authors:  Mosab Arafat; Cathrin Kirchhoefer; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

6.  Inhibition of flucloxacillin tubular renal secretion by piperacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Br J Clin Pharmacol       Date:  2008-11       Impact factor: 4.335

7.  Pharmacokinetics and dosage regimen of cefotaxime in cross-bred calves following single intramuscular administration.

Authors:  S K Sharma; A K Srivastava
Journal:  Vet Res Commun       Date:  1994       Impact factor: 2.459

Review 8.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

9.  Subcutaneous pharmacokinetics and dosage regimen of cefotaxime in buffalo calves (Bubalus bubalis).

Authors:  Suresh Kumar Sharma; Anil Kumar Srivastava
Journal:  J Vet Sci       Date:  2006-06       Impact factor: 1.672

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.